BPC-157, TB-500, Epithalon: what the 2026 FDA review changes

The FDA Pharmacy Compounding Advisory Committee reviewed seven peptides in July 2026. If you use any of these compounds, or follow the research on them, you have probably been wondering what the vote means in practice.

Short answer: it narrows or closes the compounding pharmacy pathway for affected compounds. It does not make them illegal. It does not eliminate access. What it does is push people away from the most quality-controlled sourcing option toward less regulated alternatives, which is an outcome nobody defending public safety should be satisfied with.

Here is the compound-by-compound picture.

BPC-157

Of all the compounds on the list, BPC-157 has the broadest research base and the largest active user community. Hundreds of rodent studies across tendon, ligament, muscle, gut, and neurological models. A mechanistically coherent story around VEGFR2 upregulation, angiogenesis, and nitric oxide modulation. Decades of off-label use with a safety profile that has not generated serious signal in the community literature.

What changes with the PCAC review: if BPC-157 is placed on the "do not compound" list, licensed pharmacies can no longer prepare it for patients under prescription. Clinics and functional medicine practices that have been prescribing it through that pathway lose the ability to do so legally.

What does not change: the compound's research use designation, the broader gray-market supply chain, and independent access. The effect is to remove the most accountable sourcing pathway without reducing demand.

See the full BPC-157 compound reference for the complete evidence overview.

TB-500

TB-500 is the synthetic fragment of Thymosin Beta-4 that has been used in veterinary settings for decades, particularly in racehorses. And has migrated into the human biohacking space based on animal data and a coherent systemic repair mechanism (actin-binding domain, cell migration, VEGF upregulation).

Like BPC-157, its human clinical trial evidence is limited. The animal and veterinary data are compelling. The community usage is extensive. And like BPC-157, the practical effect of removing it from the compounding-permitted list is not eliminating use, it is routing that use away from physician oversight.

See the full TB-500 compound reference.

Epithalon

Epithalon is a synthetic tetrapeptide studied primarily for its effect on telomerase activation and pineal gland function. The research base is thinner than BPC-157 or TB-500, and is concentrated in one Russian research group. The human data is sparse but the mechanistic premise, telomere maintenance and the aging-related decline of pineal function, is biologically serious enough to warrant continued research.

See the full Epithalon compound reference.

KPV, MOTS-c, Semax, DSIP

KPV is a tripeptide fragment of alpha-MSH with studied activity in gut inflammation and wound healing. Less mainstream but active research area, particularly in IBD models.

MOTS-c is a mitochondria-derived peptide with compelling early data on metabolic regulation and exercise response. It activates AMPK signaling and has shown effects on insulin sensitivity in rodent models. The research is early but mechanistically interesting.

Semax is a synthetic ACTH fragment widely used in Eastern European medical practice for neuroprotection and cognitive support. It has a longer track record of clinical use in Russia than most compounds on this list.

DSIP (Delta Sleep-Inducing Peptide) has the smallest research community of the seven. Studied for sleep regulation and stress response. The data is older and the following smaller.

The actual outcome question

The question worth asking is not just "what did the committee vote?" It is "what happens next, in practice, in the real world?"

If access through licensed pharmacies is restricted, the people using these compounds under physician supervision do not stop. They find other sourcing. The net effect is a reduction in medical oversight for existing users, with no corresponding reduction in use. The gray market absorbs the displaced demand. The contamination and quality risks I covered in the supply chain piece become more relevant, not less.

That is not a good public health outcome. And the people advocating for this community should be saying so loudly, not to resist all regulation, but to demand regulation that actually improves outcomes rather than regulation that looks good on paper while making real safety conditions worse.

Questions I get asked